Board Update

19th May 2025 

VENTURE LIFE GROUP PLC

("Venture Life", "VLG" or the "Company")

Board Update

Venture Life (AIM: VLG), a leader in developing, manufacturing and commercialising products for the self-care market, provides an update regarding the Board of the Company.

On 4th February 2025 the Company announced that due to potential conflict of interests, Mr Paul McGreevy had notifed the Board of his intention to step down from the Board at the time of the announcement of the annual results for the year ended 31st December 2024.

Due to recent changes in circumstances at both the Company and Mr McGreevy's other interests, the potential conflict of interest previously identified no longer exists. As a result, Mr McGreevy has informed the Board that he no longer needs to step down. The Board has acknowledged and accepted this notification, and Mr McGreevy will now remain on the Board as Chair. Commensurate with this the Board will therefore not be seeking to appoint a replacement non-executive director at this time, as Mark Adams will retain the role of non-executive director and Chair of the Audit Committee.

Jerry Randall, Chief Executive Officer, commented: "I am delighted that Paul is able to continue to chair the Company. Since joining us Paul has contributed significantly to the development of the Company and I am sure he will continue to do so."

For further information, please contact:

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on commercialising products for the global self-care market. Headquartered in the UK, the Group's product portfolio includes Balance Activ in the area of women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, the Health and Her product range supporting the hormonal lifecycle, the UltraDEX and Dentyl oral care product ranges. The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples and are sold in over 90 countries worldwide. In the UK, Ireland and the US these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners.